Zobrazeno 1 - 10
of 91
pro vyhledávání: '"Gilles Uzé"'
Autor:
Sandra Van Lint, Alexander Van Parys, Bram Van Den Eeckhout, Niels Vandamme, Stephane Plaisance, Annick Verhee, Dominiek Catteeuw, Elke Rogge, Jennifer De Geest, Nele Vanderroost, Jana Roels, Yvan Saeys, Gilles Uzé, Niko Kley, Anje Cauwels, Jan Tavernier
Publikováno v:
Molecular Cancer, Vol 22, Iss 1, Pp 1-21 (2023)
Abstract Despite major improvements in immunotherapeutic strategies, the immunosuppressive tumor microenvironment remains a major obstacle for the induction of efficient antitumor responses. In this study, we show that local delivery of a bispecific
Externí odkaz:
https://doaj.org/article/72e457857a534bb8861f2b6b4e37b51c
Autor:
Anje Cauwels, Sandra Van Lint, Elke Rogge, Annick Verhee, Bram Van Den Eeckhout, Shengru Pang, Marco Prinz, Niko Kley, Gilles Uzé, Jan Tavernier
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-10 (2021)
Abstract Type I Interferon (IFN) was the very first drug approved for the treatment of Multiple Sclerosis (MS), and is still frequently used as a first line therapy. However, systemic IFN also causes considerable side effects, affecting therapy adher
Externí odkaz:
https://doaj.org/article/2d42a731cebf4e52a6429aa1ceb3e0ed
Autor:
Leander Huyghe, Alexander Van Parys, Anje Cauwels, Sandra Van Lint, Stijn De Munter, Jennyfer Bultinck, Lennart Zabeau, Jeroen Hostens, An Goethals, Nele Vanderroost, Annick Verhee, Gilles Uzé, Niko Kley, Frank Peelman, Bart Vandekerckhove, Peter Brouckaert, Jan Tavernier
Publikováno v:
EMBO Molecular Medicine, Vol 12, Iss 2, Pp 1-15 (2020)
Abstract Systemic toxicities have severely limited the clinical application of tumor necrosis factor (TNF) as an anticancer agent. Activity‐on‐Target cytokines (AcTakines) are a novel class of immunocytokines with improved therapeutic index. A TN
Externí odkaz:
https://doaj.org/article/0c182dbd4d474d4e99086c5f110eebd3
Autor:
Bram Van Den Eeckhout, Leander Huyghe, Sandra Van Lint, Elianne Burg, Stéphane Plaisance, Frank Peelman, Anje Cauwels, Gilles Uzé, Niko Kley, Sarah Gerlo, Jan Tavernier
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 11 (2021)
Externí odkaz:
https://doaj.org/article/d36241b88658437b966c5cf4b40f4553
Autor:
Anje Cauwels, Sandra Van Lint, Geneviève Garcin, Jennyfer Bultinck, Franciane Paul, Sarah Gerlo, José Van der Heyden, Yann Bordat, Dominiek Catteeuw, Lode De Cauwer, Elke Rogge, Annick Verhee, Gilles Uzé, Jan Tavernier
Publikováno v:
OncoImmunology, Vol 7, Iss 3 (2018)
Despite approval for the treatment of various malignancies, clinical application of cytokines such as type I interferon (IFN) is severely impeded by their systemic toxicity. AcTakines (Activity-on-Target cytokines) are optimized immunocytokines that,
Externí odkaz:
https://doaj.org/article/fe18f4ea4f164935b446279ebe4c2ff6
Autor:
Mark Livingstone, Kristina Sikström, Philippe A Robert, Gilles Uzé, Ola Larsson, Sandra Pellegrini
Publikováno v:
PLoS ONE, Vol 10, Iss 7, p e0133482 (2015)
Type-I interferon (IFN)-induced activation of the mammalian target of rapamycin (mTOR) signaling pathway has been implicated in translational control of mRNAs encoding interferon-stimulated genes (ISGs). However, mTOR-sensitive translatomes commonly
Externí odkaz:
https://doaj.org/article/adf72d568d6a4baab0cebc48ef4c7bad
Autor:
Geneviève Garcin, Yann Bordat, Paul Chuchana, Danièle Monneron, Helen K W Law, Jacob Piehler, Gilles Uzé
Publikováno v:
PLoS ONE, Vol 8, Iss 3, p e58465 (2013)
The type I interferon (IFN) family comprises 15 cytokines (in human 13α, 1β, 1ω), which exert several cellular functions through binding to a common receptor. Despite initial activation of the same Jak/Stat signalling pathway, the cellular respons
Externí odkaz:
https://doaj.org/article/5b725855f4c846569b165913755ce5c8
Autor:
Véronique François-Newton, Gabriel Magno de Freitas Almeida, Béatrice Payelle-Brogard, Danièle Monneron, Lydiane Pichard-Garcia, Jacob Piehler, Sandra Pellegrini, Gilles Uzé
Publikováno v:
PLoS ONE, Vol 6, Iss 7, p e22200 (2011)
Type I interferons (IFN) are cytokines that are rapidly secreted upon microbial infections and regulate all aspects of the immune response. In humans 15 type I IFN subtypes exist, of which IFN α2 and IFN β are used in the clinic for treatment of di
Externí odkaz:
https://doaj.org/article/47e7dd4564f646d093a276413c75f4a2
Autor:
Jan Tavernier, Gilles Uzé, Niko Kley, Bart Vandekerckhove, Annick Verhee, Elke Rogge, Dominiek Catteeuw, Yann Bordat, José Van der Heyden, Sarah Gerlo, Thomas Wueest, Alexander Van Parys, Stefaan De Koker, Geneviève Garcin, Franciane Paul, Sandra Van Lint, Anje Cauwels
Combination treatments of B16 tumors with Clec9A-mAFN do not cause toxicity, in contrast to combinations with WT mIFN.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::10da8f73a034c988aea8adf63797b9c7
https://doi.org/10.1158/0008-5472.22418085
https://doi.org/10.1158/0008-5472.22418085
Autor:
Jan Tavernier, Gilles Uzé, Niko Kley, Bart Vandekerckhove, Annick Verhee, Elke Rogge, Dominiek Catteeuw, Yann Bordat, José Van der Heyden, Sarah Gerlo, Thomas Wueest, Alexander Van Parys, Stefaan De Koker, Geneviève Garcin, Franciane Paul, Sandra Van Lint, Anje Cauwels
An ideal generic cancer immunotherapy should mobilize the immune system to destroy tumor cells without harming healthy cells and remain active in case of recurrence. Furthermore, it should preferably not rely on tumor-specific surface markers, as the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::16722bb643c69f183e2fde8bb14083a7
https://doi.org/10.1158/0008-5472.c.6510027.v1
https://doi.org/10.1158/0008-5472.c.6510027.v1